Perioperative Management of Acalabrutinib
For patients on acalabrutinib undergoing invasive procedures, withhold the drug for 3-7 days pre-procedure depending on bleeding risk, and resume within 24-48 hours post-procedure if hemostasis is adequate. 1
Pre-Procedure Drug Discontinuation
The FDA label for acalabrutinib (CALQUENCE) explicitly states to "consider the benefit-risk of withholding CALQUENCE for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding" 1. This recommendation is driven by acalabrutinib's hemorrhagic risk profile—major hemorrhage occurs in 3.0% of patients, with bleeding events of any grade (excluding bruising/petechiae) occurring in 22% of patients 1.
Stratify by Procedure Bleeding Risk:
- High bleeding risk procedures (intracranial, spinal, cardiac surgery, major abdominal surgery): Stop acalabrutinib 7 days before the procedure
- Standard bleeding risk procedures (most general surgeries): Stop acalabrutinib 5 days before the procedure
- Low bleeding risk procedures (minor dermatologic, dental): Stop acalabrutinib 3-4 days before the procedure 2
A recent expert consensus specifically recommends discontinuing acalabrutinib 4 days prior to invasive dermatological or dental procedures 2.
Critical Bleeding Risk Considerations
Acalabrutinib carries a 3.0% major hemorrhage rate, with fatal hemorrhage in 0.1% of patients 1. The risk increases when combined with antithrombotic agents (3.6% vs 2.7% without anticoagulation) 1. Do not initiate or continue acalabrutinib in patients on dual antiplatelet therapy (aspirin plus clopidogrel) 2.
For patients on single antiplatelet agents or anticoagulation, carefully weigh the thrombotic risk against bleeding risk. The general perioperative antiplatelet guidelines suggest continuing aspirin for most procedures 3, 4, but acalabrutinib's additive bleeding risk may necessitate holding both agents.
Post-Procedure Resumption
Resume acalabrutinib within 24-48 hours after the procedure once adequate hemostasis is confirmed and there is no active bleeding 1, 2. The expert consensus specifically recommends resumption 48 hours post-procedure in the absence of bleeding 2.
Post-Operative Monitoring Requirements:
- Monitor surgical site for bleeding complications
- Check complete blood counts, particularly platelet counts (acalabrutinib causes Grade 3-4 thrombocytopenia in 10% of patients) 1
- Delay resumption if platelet count <50 × 10⁹/L or if there is ongoing bleeding
- Watch for signs of infection (19% serious infection rate with acalabrutinib) 1
Additional Perioperative Precautions
Cytopenias:
Acalabrutinib causes Grade 3-4 cytopenias including neutropenia (26%), thrombocytopenia (10%), and anemia (10%) 1. Obtain baseline CBC within 1 week of surgery and ensure:
- Absolute neutrophil count >1.0 × 10⁹/L (to reduce infection risk)
- Platelet count >50 × 10⁹/L (ideally >75 × 10⁹/L for major surgery)
- Hemoglobin >8 g/dL
Infection Risk:
With a 19% rate of serious infections (including 6% pneumonia) 1, consider perioperative antibiotic prophylaxis for high-risk procedures. Monitor closely for post-operative infections, particularly respiratory tract infections.
Drug Interactions:
Ensure hospital pharmacists review all perioperative medications for CYP3A interactions 2. Avoid strong CYP3A inhibitors (increase acalabrutinib toxicity) and inducers (decrease efficacy) during the perioperative period.
Common Pitfalls to Avoid
- Do not resume acalabrutinib too early: Wait for confirmed hemostasis, not just completion of surgery
- Do not ignore platelet counts: Thrombocytopenia may worsen bleeding risk even after drug discontinuation
- Do not overlook infection prophylaxis: The immunosuppressive effects persist beyond drug discontinuation
- Do not forget cardiovascular monitoring: Acalabrutinib causes atrial fibrillation in 4.1% of patients; perioperative stress may precipitate arrhythmias 1